Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health
Oral versions of GLP-1s have also been approved, though they thus far have lower efficacy
Twenty-five serious side effects occurred in 18 participants (17.6%) in the placebo arm and seven participants (6.9%) in the treatment arm
GHK-Cu for acne scars and texture A serum sits on the surface layer, even when it is well-made, so more severe acne scars can stay stubborn with topical care alone for months or years
We hear this a lot but most patients are surprised by how simple the weekly injection is
Our guides to tirzepatide constipation treatment , GLP-1 constipation relief , tirzepatide diarrhea duration , tirzepatide bloating , and sulfur burps on GLP-1 address each GI manifestation specifically